Points to consider for ethics committees in human gene therapy trials

Area of Science:

• Biomedical Ethics
• Gene Therapy Research
• Clinical Trial Safety

Background:

• Human gene therapy (HGT) has encountered significant ethical issues, highlighted by adverse events and patient deaths.
• Existing ethical discussions surrounding HGT are insufficient for safe clinical application.
• The death of Jesse Gelsinger underscores the urgent need for a comprehensive ethical review of HGT.

Purpose of the Study:

• To address deficiencies in the ethical discourse surrounding HGT.
• To develop strategies for the safer clinical application of HGT.
• To critically evaluate scientific and ethical aspects of HGT.

Main Methods:

• Evaluation of preclinical HGT research, including vector safety (viral vectors) and administration methods.
• Analysis of toxicity assessment for gene therapies and vector specificity.
• Examination of ethical procedural aspects: informed consent and patient-researcher relationships.

Main Results:

• Identified gaps in current ethical frameworks for HGT.
• Highlighted concerns regarding vector toxicity, specificity, and gene expression.
• Exposed conflicts of interest within HGT research regulations.

Conclusions:

• Proposes a dual approach: scientific evaluation of HGT and procedural ethics.
• Emphasizes the need for enhanced risk assessment expertise and clearer regulations.
• Aims to improve patient safety in HGT trials and facilitate efficient therapeutic application.